Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO 2021 | ARAMIS: darolutamide in patients with nmCRPC

Neal Shore, FACS, MD, Carolina Urologic Research Center, Myrtle Beach, SC, provides an outline of the Phase III ARAMIS trial (NCT02200614) of darolutamide in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC). Patients receiving darolutamide twice daily reached the primary and secondary endpoints of metastasis-free survival and overall survival (OS) respectively. Incidences of adverse events (AEs) such as fractures and cognitive impairment were additionally lower compared to other androgen receptor inhibitors (ARIs). This interview took place at the American Society of Clinical Oncology (ASCO) 2021 Virtual Meeting.